Treatment Refractory Soft Tissue Myoepithelial Carcinoma with an ARID1A Mutation

Cody R. Ashcroft, Scott W. Penney, Susan L. Whiteway*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Soft tissue myoepithelial carcinoma is a rare tumor first reported in the salivary gland. There is considerable tumor heterogeneity between pathology findings, tumor aggressiveness, and response to treatment. Recent molecular testing has identified recurrent genetic changes with PLAG mutations in salivary gland primary tumors and loss of SMARCB1 and EWSR1/FUS gene changes in myoepithelial carcinoma. SMARCB1 is a component of the switch/sucrose nonfermentable (SWI/SNF) complex, an essential cellular regulator. ARID1A is another SWI/SNF complex subunit and is a potent oncogenic driver in other tumor types. In this case, we describe the case of an adolescent/young adult patient with treatment refractory soft tissue myoepithelial carcinoma and a previously unreported ARID1A mutation.

Original languageEnglish
Pages (from-to)E539-E542
JournalJournal of Pediatric Hematology/Oncology
Volume45
Issue number4
DOIs
StatePublished - 1 May 2023

Keywords

  • ARID1A
  • soft tissue myoepithelial carcinoma
  • SWI/SNF complex

Cite this